Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With the M&A activity of this sector, Facebook going public, IMO, the environment is becoming "friendly" again to be speculative. And hopefully, will remain so. This is good for our sector, and equities in general.
IMO, now is a very good time for Bellicum to raise money via public offering. I have no idea what their internal numbers look like, but, its becoming a good time for "easy money". Hopefully Eurozone doesn't become a wet blanket again.
congrats!
OMG let me guess...bear raid brought it down?
:o)
I dont show any trades in the May6 puts.
I show (what looks like a sale) of 2030 Feb13 puts, at .10 cents
This is your largest weighted holding right? Seems right up your alley, fundamentals and all.
LOL :)
How about it being this simple: the stock tracked the broader market down.
LOL! Cmon. MNTA has nothing to do with this reversal. Entirely different market/product. ARIA is doing nothing but following the broader market movements.
Yes, "slightly" better than Donn Wilson's Yougurt small business.
What was that other scam company that had some THC compound? PARS?
It would sound great to me. Even better if there were multiple bidders, lol.
I would prefer a gap closure in 5 years (after it goes to $20 first). lol
Lung cancer immunotherapies, slides
http://e-syllabus.cancerlearning.com/_media/files/lcc2011/Bazhenova%20slides%208_14%20855am%20PRINT.pdf
2- Announcement of preclinical studies of a new molecule (our 5th drug)
CLL treatment (immunotherapy)- fyi
http://www.msnbc.msn.com/id/44498065/ns/health-the_new_york_times/#.TxW-Y5h6d95
Rindopepimut is simply a 13 amino acid peptide attached to a carrier protein (KLH in this case). So the body has to ramp up an immune response against this peptide. This has historically been a relatively failing proposition in producing an adaptive immune response: you get low titre B-cell derived antigen specific antibodies and a weak T cell response. This is very similar to BLP25.
LOL, i agree. An "upgrade" by Rachel McMinn is meaningless. In fact, Rachel McMinn is meaningless.
commonly referred to as a nuke
Exactly. That is a great takeaway from the INHX document.
Someone got out bid, and left in the cold. That someone sounds fairly desperate to acquire an HCV type asset. I cannot see how this is anything but bullish for the remaining small independent players in this field.
Wish I owned something in this space :(.
I have a friend who works for a mega law firm involved in a lot of these transactions. In the final days, weeks of these transactions, he literally gets nap time sleep. There is no, going home and getting a few hours.
These deals make the firm's year.
And for their unpartnered drugs?
Couldn't ask for clearer proof that many small biotechs really haven't a clue when it comes to clinical trial design/prediction
that there are too many freaking investment bankers taking too large a cut of the pie.
The takeaway to this is that there is at least one other major pharma out there actively seeking an HCV asset to acquire, or to acquire an entire company.
Really interesting read.
This is a great great read.
Thanks for posting this.
INHX..insider trades?
http://www.zerohedge.com/news/inhibitex-deal-leaked-or-just-exceptional-timing
How to you "upgrade" a buy? Oh wait, maybe to a "strong buy", but only the cheesiest of firms still use "strong buy". It is either SELL BUY or HOLD as far as I am concerned.
Is the difference between STRONG BUY and BUY like buying with 2 hands, instead of just one?
Merck Lawsuit Settlement
fwiw, i have no idea if this is even important or not.
8-K
http://sec.gov/Archives/edgar/data/310158/000119312512012016/d283226dex991.htm
Looks like someone bought a bunch of May 6, 7 PUTS today.
IMO, probably a hedge against a long position considering the action of the stock today.
2012 in Mid-Cap Biotech
MERGER MONDAYS and
TAKEOVER TUESDAYS!!!
:)
And who are the 5?
All I know is three really bad (if still 3) firms covering:
Craig Hallum
B Riley
Northland
All third fourth tier firms with no following
You might want to take this talk to the yahoo board. (if not there already) EGHT might hit $12.00 by end of year
True.. considering the CEOs probably do a road-show, winking and nodding the whole way through it, about raising money. wink wink
Gives absolutely no confidence to your own drug at all.
Shorting a PIPE or secondary and covering with the shares is supposed to be illegal. How is it, that after all these deals, in many companies, it is clear as day, to even a novice investor, that this is what is going on, yet, the morons at the proper authorities have done NOTHING about this.
Actually, the SEC fined two retail investors for shorting into secondaries and covering with the shares.....yes, retail guys.
Until, as usual, they disappoint.
The stock has gone steadily down since these nimrods missed their last Q by .02 cents - if the donkey CEO and CFO actually "guided" EPS lower due to the acquisition, it wouldnt have been a "surprise".
Their guidance sucks, which is why they have two awful analysts covering the company and no one else willing to pick up coverage. Their management isnt well liked (understatement) by anyone on the Street.
LMFAO.... and you know...someone..somewhere (most likely on Yahoo MB)...still...thinks...once...pixantrone is approved.....the stock should go back to $15,000/share.
Why does any entity continue to fund this company. If they stop giving them money in these PIPES the company aka ponzi runs out of money. Game over.
These guys should be arrested
Yeah, I agree. Thankfully, Merck has control over the Stimuvax program. I think Kirkman is kind of a babbling idiot. Not a scummy one like a lot of CEO's, just simply, a marble-mouth.
But then again, who knows what he really said. It was done by Reuters and those guys are clowns and misquote all the time.
IMO, gone are the mega-deals, and we're now in mid-sized deals for R&D.
THIS IS THE YEAR TO OWN BIOTECH